On-site display of pharmaceutical technology and group photo of all staff at the 2019 Medical Technology Exhibition. Development of ADHD and Epilepsy Drugs: Application of New Pharmaceutical Technologies Focusing on the research and development of FDA-regulated 505(b)2 new drugs and niche pharmaceuticals, AUO possesses the "Multi-Level Drug Delivery Technology", in which the "Thermal Fusion Controlled Delivery Technology" develops a new drug for ADHD, which combines a slow-release and a fast-release drug into a single capsule, and a new drug for epilepsy, which is a new drug for epilepsy. One of these technologies is the Thermal Fusion Controlled Release Technology, which has developed a new drug for hyperactivity disorder that combines slow-release and rapid-release drugs into one capsule. Another "Triple Particle Controlled Release Technology", in collaboration with an American company, has produced a drug for epilepsy, which has already been marketed in China, and in November this year, the Group also acquired a second indication for migraine.
Three-particle controlled release technology and a U.S. company are working together to produce a drug for epilepsy that is already on the market in China. Cancer injection factory High-end equipment to prevent cross-contamination and increase safety